Albumin Counteracts Immune-Suppressive Effects of Lipid Mediators in Patients With Advanced Liver Disease by China, L et al.
Clinical Gastroenterology and Hepatology 2018;16:738–747Albumin Counteracts Immune-Suppressive Effects of Lipid
Mediators in Patients With Advanced Liver DiseaseLouise China,* Alexander Maini,* Simon S. Skene,‡ Zainib Shabir,‡ Yvonne Sylvestre,‡
Romain A. Colas,§ Lucy Ly,§ Natalia Becares Salles,* Vittorio Belloti,* Jesmond Dalli,§
Derek W. Gilroy,* and Alastair O’Brien*
*Division of Medicine, University College London, London, United Kingdom; ‡University of London Comprehensive Clinical
Trials Unit, London, United Kingdom; and §Barts and The London School of Medicine and Dentistry, Queen Mary University of
London, London, United KingdomBACKGROUND & AIMS:Abbreviations used in this pape
acute decompensation; CI, con
HAS, human albumin solution;
lipopolysaccharide; MDM, m
prostaglandin E2; SD, standar
WCC, white cell count.Patients with acute decompensation and acute-on-chronic liver failure (AD/ACLF) have immune
dysfunction, which increases their risk for infections; however, there are no effective treatments
to restore their immune function. We investigated whether the potentially immune-restorative
effects of albumin are mediated by its effects on prostaglandin E2 (PGE2) and other lipids.METHODS: We analyzed bloods samples from 45 of 79 patients with AD/ACLF and serum levels of albumin
less than 30 g/L forwhom infusion of 20%human albumin solution (HAS) increased serum levels
of albumin 30 g/L or more in a feasibility study of effects of 20% HAS. Immune function was
determined by comparison of macrophage function following addition of plasma samples. We
also used samples from 12 healthy individuals. Wemeasured binding of plasma proteins to PGE2
and serum levels of endotoxin (lipopolysaccharide) and cytokines; using 10 patients’ samples, we
investigated the effects of PGE2 inhibitors. We performed a comprehensive lipid metabolomic
analysis using samples from 10 different patients, before and after HAS administration.RESULTS: At baseline, AD/ACLF patient plasma induced signiﬁcantly lower production of tumor necrosis
factor by healthy macrophages than plasma from healthy individuals (P < .0001). Plasma from
patients after HAS infusion induced signiﬁcantly higher levels of tumor necrosis factor produc-
tion by macrophages (19.5 – 4.8 ng/mL) compared with plasma collected before treatment
(17.7 – 4.5 ng/mL; P [ .0013). There was a signiﬁcantly lower proportion of plasma protein
(albumin) binding to PGE2 from patients with AD/ACLF plasma (mean, 61.9%) compared with
plasma from control subjects (77.1%; P [ .0012). AD/ACLF plasma protein binding to PGE2
increased following HAS treatment compared with baseline (mean increase, 8.7%; P < .0001).
Circulating levels of PGE2, lipopolysaccharide, and inﬂammatory or anti-inﬂammatory cytokines
werehigher in patientswithAD/ACLF thanhealthy volunteers. Unexpectedly, HAS infusionhadno
effect on mediator levels. Principal component analysis of baseline levels of lipids that induce or
resolve inﬂammation identiﬁed 2 distinct groups of patients that differed according to baseline
plasma level of lipopolysaccharide. Sample analyses after HAS treatment indicated that albumin
regulates circulating levels of lipid mediators, but this effect was distinct in each group.CONCLUSIONS: Analysis of bloodsamples frompatientswithAD/ACLFparticipating ina feasibility studyof20%HAS
infusions has shown that infusions to raise serum albumin above 30 g/L reversed plasma-mediated
immune dysfunction by binding and inactivating PGE2. We also describe a method to classify the
inﬂammatory response in AD/ACLF, based on lipid proﬁle, which could improve identiﬁcation of
patients most likely to respond to HAS treatment. A randomized controlled trial is needed to
determine whether these effects of HAS reduce infections in AD/ACLF. Trial registered with
European Medicines Agency (EudraCT 2014-002300-24) and adopted by NIHR (ISRCTN14174793).Keywords: ATTIRE Trial; Resolution Phase Lipid Mediators; Immune Regulation; ALD.r: ACLF, acute-on-chronic liver failure; AD,
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defective immune response in patients with acuteAdecompensation (AD) or acute-on-chronic liver fail-
ure (ACLF) is widely considered to underlie susceptibility
to bacterial infection.1–3 However, despite multiple studies
the mechanisms underlying immune dysfunction in
AD/ACLF remain unclear. We developed a model in
which healthy volunteers’monocyte-derived macrophages
(MDMs) were incubated with plasma from patients with
AD/ACLF and measured tumor necrosis factor (TNF) pro-
duction, a validatedmarker ofmonocyte function in critical
illness.4 Using this model, we demonstrated elevated
plasma prostaglandin E2 (PGE2) and its potential role in
immune suppression in patients with AD/ACLF. We also
proposed a beneﬁcial effect of transfusing 20% human
albumin solution (HAS) to antagonize PGE2’s effects.
5
Albumin has been reported to bind and catalyze PGE2
inactivation.6 Albumin is synthesized in the liver, therefore
levels decrease in AD/ACLF, and so PGE2 should be more
bioavailable. Defective functional binding capacity of albu-
min has been described in cirrhosis,7 again theoretically
further enhancing bioavailability of PGE2. However the
actual PGE2-albumin binding relationship in liver disease
has never been explored. Studies have shown other poten-
tial immunomodulatory roles for albumin8,9 but these have
used samples from single center observational cohorts.
We performed immune function analysis of patients
with AD using samples collected from a feasibility trial in
preparation of the ATTIRE trial (Albumin To prevenT
Infection in chronic liveR failure). Our feasibility trial
included79patientswithAD/ACLFwho received20%HAS.
An accompanying manuscript in this issue details the clin-
ical outcomes of these patients. The current article provides
mechanistic insights into the potential immune restorative
effect of targeted 20% HAS infusions in AD/ACLF.
Speciﬁcally, we aimed to conﬁrm that elevated
circulating PGE2 levels contributed to immune suppres-
sion; examine whether exogenous albumin improved
PGE2-albumin binding and/or increased catalysis;
compare PGE2 binding in commercial albumin prepara-
tions; determine whether any improvement in immune
dysfunction observed following 20% HAS infusion was
via a PGE2 effect; and examine the potential interaction
of infused albumin with other plasma lipids (including
proresolving mediators, molecules with host protective
actions10), proinﬂammatory and anti-inﬂammatory
cytokines, and endotoxin. Finally, we correlated
laboratory ﬁndings with patient clinical characteristics.
Methods and Analysis
Study Design and Patients
ATTIRE’s protocol paper was published11 and the full
protocol is available online. Ethical approval was grantedby London-Brent research ethics committee (ref:15/LO/
0104). All authors had access to study data and reviewed
and approved the ﬁnal manuscript. Studies were per-
formed as follows with laboratory researcher blinded to
whether the sample was pre- or post-HAS infusion.Laboratory Outcomes
The key secondary endpoint for ATTIRE feasibility
study was change in immune function determined by
patient plasma-induced healthy volunteer MDM
dysfunction, as measured by endotoxin-stimulated TNF
production (lipopolysaccharide [LPS]; Salmonella
abortus equi S-form [TLRgrade, Enzo Life Science], NY),
for 4 hours in presence of 25% patient plasma pre- and
post-HAS treatment. TNF was measured with enzyme-
linked immunosorbent assay (R&D systems, MN) as
previously.5 Plasma samples analyzed were from
admission (pre-HAS infusion) compared with samples
once serum albumin had reached 30 g/L. The same
assay was repeated using a monocyte cell line (mono-
mac 6) for validation. Experiments were in a single
centralized laboratory. Laboratory and matching clin-
ical data were exchanged simultaneously between
researcher and statisticians at the Comprehensive
Clinical Trials Unit at University College London
(Supplementary Methods).Plasma Protein Binding Capacity
Paired plasma samples pretreatment/post-treatment
with 20% HAS were obtained from 52 of 79 patients in
the ATTIRE feasibility trial. In 45 of 52 patients, the post-
treatment sample corresponded to restoration of serum
albumin 30 g/L (the primary endpoint) on mean
treatment day 3.29 (standard deviation [SD], 1.27).
These patients had mean pretreatment serum albumin
23.98 g/L (range, 12–29 g/L). In the other 7 of 52
patients the post-treatment sample was when patient
had reached highest serum albumin level, and a sample
had been taken that day. Plasma PGE2 binding was
assessed in these samples with healthy volunteer
samples (n ¼ 12) as comparator.
The amount of PGE2 bound by plasma was deter-
mined using equilibrium dialysis (Thermo Scientiﬁc
Single-Use RED [rapid equilibrium dialysis] Plate, IL),
which enabled quantiﬁcation of bound versus free
PGE2 via postdialysis sample scintillation counting
(Supplementary Methods). The 20% HAS from
commercial suppliers Zenalb (BPL Herts, UK), Albu-
norm (Octapharm, Manchester, UK), and Alburex (CSL
Behring, West Sussex, UK) including 2 different
batches of Zenalb and Alburex were assessed and
compared with fatty acid free albumin from human
serum (Sigma-Aldrich, UK). Albumin concentration was
diluted to 20 g/L (300 mM) and checked using
bromocresol green.
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We selected (while blinded) aliquots from 10 sam-
ple pairs that had showed at least a 15% difference in
MDM TNF production following HAS infusion. A total of
15% was considered representative because 20% HAS
infusions produced a mean >14% increase in MDM
TNF (see results section). Experiments were
performed with healthy volunteer plasma as compar-
ator. PGE2 receptor antagonists AH6809 50 mM (EP1-3
antagonist) and MF498 10 mM (EP4 antagonist) (ie,
pan PGE2 receptor blockade) were added to samples
before LPS stimulation and TNF measured. Samples
from Days 4, 5, and 10 of HAS treatment were also
used.Lipopolysaccharide Detection and
Cytokine Measurement
LPS and proinﬂammatory and anti-inﬂammatory
cytokines were assayed in the 45 paired patient plasma
samples using HEK293 cells and BD Cytometric Bead
Array Human Soluble Protein Kit (BD Biosciences,
Oxford, UK) (Supplementary Methods).Lipid Mediator Metabolomic Data
Samples from 10 patients pre- and post-HAS infusion
from a top recruiting sites were chosen for analysis in
view of the complexity of processing required and need
for standardized collection and storage (Supplementary
Methods).Statistical Analysis
For plasma analysis (a-d) a paired Student t test
compared pre- and post-HAS treatment groups (Prism 7,
CA). For lipid metabololipidomic analyses, Simca 14.1
(Malmo, Sweden) was used as below.Results
Recruitment and Baseline Characteristics
Baseline characteristics were as follows: mean
age, 53.4 years; male, 66%; and alcohol primary
cause of cirrhosis, 96% (Supplementary Table 1).
Mean Model for End-Stage Liver Disease score was
20.9 (SD, 6.62); 17 of 79 patients had 1 extra
hepatic organ dysfunction at baseline and 21 (27%)
ACLF grade 1–3. Baseline albumin levels were <25
g/L in 67%.Plasma-Mediated Immune Dysfunction
Pre– and Post–20% Human Albumin
Solution Infusions
Patient plasma treatment signiﬁcantly reduced
endotoxin (LPS)-stimulated production of TNF from
healthy MDMs compared with healthy volunteer plasma
(P < .0001) (Figure 1A). There was a signiﬁcant
increase in MDM TNF production of 14.3% (95% con-
ﬁdence interval [CI], 5.1%–23.5%; 17.7  4.5 ng/mL to
19.5  4.8 ng/mL; P ¼ .0013) (Figure 1B) following
addition of post-HAS treatment plasma compared with
pretreatment from 45 paired samples. In total, 30 of
45 (78%) had improved MDM TNF production
post-treatment. A differentiated monocyte cell
line showed similar ﬁndings of 10.2% (95% CI,
2.5%–17.9%; P ¼ .014) (Supplementary Figure 1A).
There was a trend toward increased TNF production
from patients not incrementing 30 g/L (n ¼ 7)
compared with pretreatment (Supplementary
Figure 1B). There was no change in mean white cell
count (WCC) or C-reactive protein (CRP) between pre
and post samples but serum bilirubin was reduced by a
mean 25% (Supplementary Table 2).Targeted 20% Human Albumin Solution
Infusions Improved Acute Decompensation
and Acute-on-Chronic Liver Failure Plasma
Ability to Bind Prostaglandin E2 Both by
Increasing Albumin Concentration and
Functional Capacity With No Effect on
Overall Prostaglandin E2 Concentration
Plasma PGE2 concentrations pretreatment were
highly variable but substantially elevated with a mean
52.5 pg/mL (SD, 44.6; n ¼ 10) compared with
published healthy volunteer concentrations using this
technique (mean, 4.1; SD, 0.2 pg/mL).12 Albumin
infusion had no overall effect on total plasma PGE2
concentrations, which measure free and albumin-bound
PGE2 (pretreatment, 52.5 [13.4] pg/mL vs
post-treatment, 49.9 [8.1] pg/mL) (Supplementary
Tables 3 and 4).
Albumin bound PGE2 with very low afﬁnity and
calculated dissociation constant was approximately
280 mM. This low binding afﬁnity suggests that
decreasing serum albumin to AD/ACLF patient levels
combined with observed increases in PGE2 concen-
tration could result in increases in free circulating
PGE2 to pathophysiological levels. To illustrate this we
performed theoretical calculations (Supplementary
Table 5).
AD/ACLF plasma bound a mean of 15.2% less PGE2
compared with healthy volunteer plasma (n ¼ 12;
77.1% vs 61.9%; P ¼ .0012). The 45 paired patient
samples showed an improved ability to bind PGE2
Figure 1. Targeted 20% HAS infusions reverse immune dysfunction in AD/ACLF by improving ability of patients with AD/
ACLF plasma to bind PGE2. (A) Endotoxin (LPS) stimulated MDM TNF production in presence of patient plasma
pretreatment with 20% HAS (n ¼ 45 patients) compared with nonautologous healthy volunteer plasma. LPS MDMs TNF
production in presence of healthy volunteer plasma was 6.88 ng/mL more in presence of AD plasma (CI, 4.85–8.91 ng/mL;
P < .0001). (B) LPS MDM TNF production in presence of plasma pre- and post-HAS treatment (n ¼ 45 patients
incremented serum albumin >30 g/L). Mean post-treatment TNF increase 1.75 ng/mL (0.72–2.77; P ¼ .0013), 14.5%
(5.1%–23.5%). (C) Percentage PGE2/
3H-PGE2 bound to healthy volunteer and AD/ACLF plasma protein using equilibrium
dialysis. Post-HAS treatment plasma binds more PGE2 than pre-HAS (mean increase, 8.7%; CI, 5.2%–12.1%; P < .0001;
n ¼ 45). (D) Percentage PGE2/3H-PGE2 bound in different HAS products or Sigma albumin diluted to 20 g/L albumin in
phosphate-buffered saline (n ¼ 3). (E) LPS MDM TNF production in presence of pretreatment patient plasma (n ¼ 10)
in presence/absence of EP2 (AH6890-50 mM) and EP4 (MF498-10 mM) receptor antagonists compared with
post-treatment effect. (F) LPS MDM TNF production in presence of AD/ACLF plasma Day 5 and 10 post-treatment with
20% HAS.
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CI, 5.2%–12.1%; P < .0001) (Figure 1C).
The binding may have improved because of increased
plasma albumin concentration following treatment. To
investigate functional alterations in binding we selected
23 patient samples with a greater or equal improvement
in binding compared with overall mean 8.7% PGE2
bound (mean, 16.1%; 95% CI, 6.0%–15.0%; P < .0001).
Pretreatment and post-treatment plasma was diluted to
18 g/L albumin and post-treatment plasma bound
signiﬁcantly more PGE2 than pretreatment (mean
increase, 10.9%; 95% CI, 5.2%–16.7%; P ¼ .0007)(Supplementary Figure 1C) suggesting functional
improvement in binding capacity.Commercially Available 20% Human Albumin
Solution Tested Bound Prostaglandin E2 to a
Similar Degree
There were no signiﬁcant differences in
PGE2 binding among samples tested (Figure 1D) and
values were less than healthy volunteer plasma
binding.
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to Improve Immune Function in Patients With
Acute Decompensation and Acute-on-Chronic
Liver Failure by Reversing the Immune
Suppressive Effect of Prostaglandin E2
With Effect Maintained to at Least
Day 10 of Treatment
LPS-induced TNF production from MDMs pretreated
with pan-PGE2 receptor blockade (EP1-3-AH6890 and
EP4-MF698) before addition of pre-HAS treatment
plasma was increased to a similar level as when
post-HAS plasma was added (without PGE2 antagonists).
Mean increase was 3.51 ng/mL (P ¼ .0013; 95% CI,
1.78–5.24) (Figure 1E). However pan-PGE2 receptor
blockade had no signiﬁcant effect on MDMs treated with
post–20% HAS plasma (P ¼ .0945). These antagonists
had no effect on MDM TNF production when added to
healthy plasma samples (Supplementary Figure 1D). The
increased MDM TNF production between pre- and
post-HAS treatment was maintained but not increased up
to Day 10 of treatment in 10 samples analyzed
(Figure 1F, Supplementary Figure 1E).Targeted20%HumanAlbuminSolution Infusions
had No Signiﬁcant Effect on Elevated Plasma
Concentrations of Lipopolysaccharide and
Proinﬂammatory/Anti-Inﬂammatory Cytokines
Seen in Patients With Acute Decompensation
and Acute-on-Chronic Liver Failure
There was a trend toward reduction but no signiﬁ-
cant differences in total plasma proinﬂammatory and
anti-inﬂammatory cytokine levels assayed (TNF,
interleukin [IL] 1b, IL6, IL10, and IL8) and LPS concen-
trations in 45 paired samples (Supplementary Table 6).Principal Component Analysis of Baseline
(Pretreatment) Inﬂammation Initiating and
Proresolving Plasma Lipid Mediators Identiﬁed
2 Distinct Acute Decompensation and
Acute-on-Chronic Liver Failure Patient Groups
and Targeted 20% Human Albumin Solution
Infusions Demonstrated Distinct Responses
Between These Groups
We investigated plasma lipid mediator (LM) proﬁles
for essential fatty acid–derived (docosahexaenoic acid,
n-3 docosapentaenoid acid, eicosapentaenoic acid, and
arachidonic acid), proresolving mediators: resolvins,
protectins, maresins, and lipoxins in 10 plasma samples
pre–20% HAS infusion and once serum albumin had
reached 30 g/L following treatment. We quantiﬁed the
classic inﬂammation-initiating eicosanoids (prostaglan-
dins, thromboxane B2, and leukotrienes). Identiﬁcationwas conducted in accordance with published criteria
including matching retention time and at least 6 diag-
nostic ions in tandem mass spectrum12 (Figure 2,
Supplementary Tables 3 and 4).
We identiﬁed mediators from each major essential
fatty acid metabolome including 13 series resolvins 1,
protectins 1, and lipoxins A4. Using multivariate analysis
of plasma LM proﬁles pre and post albumin treatment
we found that each of these groups segregated into 2
distinct clusters (Figure 3A and B). These data indicate
that albumin treatment regulates circulating LM levels.
However, overall LM levels pre and post albumin treat-
ment did not demonstrate statistically signiﬁcant
changes (Supplementary Tables 3 and 4). Therefore, we
questioned whether responses in plasma LM proﬁles
following albumin were dependent on pretreatment LM
levels.
Principal component analysis of pretreatment LM
proﬁles identiﬁed 2 distinct patient groups characterized
by 5 patients per group (Figure 3B). Assessment of LM
proﬁles in each group pre albumin treatment
demonstrated a hypoactivated proﬁle (Group 1) with
reduced concentrations of several proresolving and
inﬂammation-initiating mediators including n-3 docosa-
pentaenoic acid–derived protectins, AA-derived lipoxins
and prostaglandins, thromboxane B2, and leukotriene B4
(Figure 3C). The second hyperactivated group demon-
strated overall elevated LM concentrations (Group 2;
Figure 3B and C). Patients in the hyperactivated group
had elevated WCC, temperature, cytokine, and CRP levels
and statistically signiﬁcant increases in plasma endotoxin
concentration (Table 1). Investigation of peripheral
blood LM levels pre and post albumin administration
demonstrated a re-equilibration of several mediator
families. LM concentrations for several of the families
identiﬁed in the hyperactivated group were found to be
decreased, whereas in the hypoactivated group mediator
concentrations increased post albumin treatment
(Figure 4A–F). These results demonstrate that plasma
LM proﬁles identify 2 distinct patients groups,
hypoactivated and hyperactivated, and regulation of
plasma LM proﬁles by albumin is distinct in each. The
endotoxin and cytokine levels did not change signiﬁ-
cantly following HAS in either group and there was no
difference in clinical outcomes.
Discussion
This represents the ﬁrst demonstration of a potential
pharmacological immune restorative role for 20% HAS
infusions in patients with AD/ACLF through its ability
to bind PGE2 using samples from a multicenter inter-
ventional trial. We show that 20% HAS infusions
seemed to reverse AD/ACLF patient plasma-induced
macrophage dysfunction restoring TNF production to-
wards levels seen when macrophages were incubated
with healthy plasma. We had no control arm and this
Figure 2. AD/ACLF
plasma proresolving and
inﬂammation-initiating
mediator proﬁles. Plasma
collected pre and post
albumin administration
and lipid mediators
proﬁled using liquid
chromatography–tandem
mass spectrometry LM
metabololipidomics. (A)
Representative multiple
reaction chromatograms
for identiﬁed lipid media-
tors and (B) tandem mass
spectrometry spectrum
used in identiﬁcation of
AT-lipoxins A4 and MaR1.
Representative of 10
patients. AA, arachidonic
acid; DHA, docosahexae-
noic acid; DPA, docosa-
pentaenoic acid; EPA,
eicosapentaenoic acid;
m/z, mass to charge ratio.
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median time between samples was 4 days, with an
overall 25% improvement in bilirubin observed, which
cannot be excluded as a confounder. We again show
signiﬁcantly elevated prostaglandins and demonstrate
for the ﬁrst time proresolving mediators resolvins,
protectins, maresins, and lipoxins in patients with AD/
ACLF. These autacoids stimulate key cellular resolution
events, enhancing macrophage apoptotic cell clear-
ance.10 Finally principal component analysis of LMs
divided patients into a hyperinﬂammatory and hypoin-
ﬂammatory proﬁle that could be differentiated by
plasma endotoxin concentrations from 10 patients
analyzed with nonsigniﬁcantly elevated WCC, tempera-
ture, cytokine, and CRP levels. Importantly, 20% HAS
infusions seemed to equilibrate the inﬂammatory bal-
ance of inﬂammation initiating eicosanoids and pro-
resolving mediators between these groups without
affecting endotoxin or cytokine levels. These data sug-
gest a further novel immune restorative effect for
albumin.
Albumin is considered to have immune modulatory
effects in AD/ACLF13–15 but no prospective trial has
identiﬁed mechanistic action beyond volume expansion.
We previously demonstrated its potential to antagonize
the effects of PGE2 and others have suggested it bindsendotoxin or exerts a beneﬁcial effect on proin-
ﬂammatory cytokines.16–18 Immune function is an
extremely complex process and we designed a prag-
matic assay to investigate samples from multiple sites
that we have validated by showing similar effects in
freshly isolated monocytes from patients with ACLF.19
We show for the ﬁrst time in a prospective trial that
20% HAS infusion reversed the immune suppressive
effects of PGE2 in AD/ACLF by improving plasma
binding to this molecule, thereby inactivating it. This
effect persisted in samples tested to Day 10 but did not
improve once serum albumin was >30 g/L. PGE2 binds
albumin but no other plasma proteins20 and we found
albumin to have a very low binding afﬁnity for PGE2
supporting the presence of free unbound PGE2 within
plasma at pathophysiological concentrations. Albumin
infusion improved plasma protein binding to PGE2.
Studies using PGE2 (E-prostanoid) receptor antagonists
demonstrated a similar immune restorative effect to
20% HAS infusion and had no effect in samples post-
HAS infusion supporting this immune restorative
effect of albumin occurring via PGE2 inhibition. Unex-
pectedly plasma endotoxin and proinﬂammatory/
anti-inﬂammatory cytokine concentrations were unaf-
fected by albumin infusions, therefore effects observed
were not via direct modulation of these. We found no
Figure 3. Albumin administration shiftsAD/ACLFplasmaLMproﬁles andprealbuminLMproﬁles identiﬁes2distinctAD/ACLFpatient
groupswith a hyperactivated (group 2) and hypoactivated (group 1) LMphenotype. LMproﬁles interrogated using partial least square
discriminant analysis. (A) 2D score plot with baseline and post treatment plasma LM proﬁles interrogated using principle component
analysis. 2D score plot (top), 2D loading plot (bottom). (B) 2D loading plot with pre-treatment plasma pro-resolving and inﬂammation-
initiating mediators identiﬁes 2 distinct groups: group 1 (red) and group 2 (blue). (C) Assessment of lipid mediator proﬁles in each of
these groups pre albumin treatment demonstrated a hypo-activated proﬁle (Group 1) with reduced concentrations of several pro-
resolving and inﬂammation initiating mediators. The second hyper-activated group was characterized by overall elevated lipid
mediator concentrations (Group 2). Results mean  standard error of the mean, representative of 10 patients.
Table 1. Clinical Characteristics of Group 1 (Hypoinﬂammatory) and Group 2 (Hyperinﬂammatory) Patients as Deﬁned by Lipid
Mediator Principal Component Analysis at Baseline (n ¼ 5 Patients per Group)
Group 1: hypoinﬂammatory lipid
mediator proﬁle, mean (SD)
Group 2: hyperinﬂammatory
lipid mediator proﬁle, mean (SD)
MELD 18.9 (5.4) 20.1 (7.9)
Age 45.66 (13.52) 48.63 (13.85)
Pre 20% HAS Post 20% HAS Pre 20% HAS Post 20% HAS
Serum albumin (g/L) 22.4 (6.1) 28.2 (5.2) 20.8 (3) 29.6 (4.5)
Temperature (C) 36.84 (1.0) 37.96 (1.1)
White cell count (x109/L) 11.24 (4.5) 9.18 (5.83) 18.16 (14.2) 4.6 (16.4)
CRP (mg/mL) 70.8 (76) 107.0 (46.8) 92.6 (93.3) 46.0 (45.4)
Heart rate (bpm) 104.4 (14.5) Not available 106.8 (23.7) Not available
Endotoxin (pg/mL) 3.7 (2.3) 7.2 (3.5) 23.44 (12.3) 19.0 (13.3)
TNF (pg/mL) 0.75 (0.5) 3.0 (1.7) 2.27 (1.7) 5.4 (7.5)
IL1b (pg/mL) 0.67 (1.5) 1.6 (1.7) 4.13 (6.8) 2.3 (2.8)
IL6 (pg/mL) 227.7 (407.2) 7135 (6649) 898.1 (1949.4) 14,121 (31,356)
IL8 (pg/mL) 372.9 (96.9) 576.7 (285.1) 442.3 (173.2) 828.2 (1271.9)
IL10 (pg/mL) 0.6 (3.2) 120.0 (110.5) 12.9 (12.6) 239.9 (13.3)
CRP, C-reactive protein; HAS, human albumin solution; IL, interleukin; MELD, model for end-stage liver disease; SD, standard deviation; TNF, tumor necrosis factor.
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Figure 4. Albumin differentially regulates plasma LM proﬁles in patients with AD/ACLF with hyperactivated and hypoactivated
LM phenotypes. Plasma pre and post albumin administration was LM proﬁled using liquid chromatography–tandem mass
spectrometry based LM metabololipidomics and quantiﬁed using multiple reaction monitoring. (A–F) Results represent
cumulative levels of proresolving mediator and inﬂammation-initiating eicosanoids found to be regulated by albumin admin-
istration. Five patients per group per interval.
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to bind PGE2. Patients recruited to our randomized
controlled trial will be given HAS customarily used at
that site and therefore the absence of any differences
between manufacturers was important.
Overall PGE2 concentrations were unaffected by HAS
infusion, which challenges previous data demonstrating
PGE2 catalysis by albumin.
6 This observation may be
related to our assay measuring total PGE2, both free and
albumin bound. We hope to develop techniques to
differentiate between the 2 to determine whether free
PGE2 is catalyzed by albumin.
Albumin is present in low concentrations in AD/ACLF
and has decreased functional efﬁcacy7 caused by post-
transcriptional modiﬁcation.21 Administration of 20%
HAS not only improved albumin concentration but also
functional capacity to bind immunosuppressive PGE2.
Taken together these data suggest that 20% HAS
infusions act pharmacologically to improve immune
function in AD/ACLF through albumin’s ability to bind
elevated circulating levels of immunosuppressive PGE2.Its weak binding of PGE2 and lack of effect on absolute
levels may explain the absence of renal or gastrointes-
tinal side effects in contrast to nonsteroidal
anti-inﬂammatory drugs, which alter eicosanoid proﬁles
at these sites. Studies have identiﬁed structural and
functional alterations in commercial HAS compared with
healthy albumin22 and we showed reduced PGE2 binding
compared with healthy volunteer plasma. It may be the
immune effects of albumin could be enhanced with
further research. Again we observed heterogeneity in
immune dysfunction and response to albumin using our
immune assay may identify patients most likely to
beneﬁt from this approach.
A weakness was the lack of a control (untreated arm)
and therefore immune function may have improved
because of patients recovering; indeed serum bilirubin
fell by 25% between samples. However the CRP and
WCC were unchanged, and we previously showed
immune dysfunction in AD persisted throughout hospital
admission.10 Furthermore, plasma cytokine and endo-
toxin levels did not alter between pre- and post-HAS
Figure 5. Schematic version of our hypothesis that prophylactic human albumin infusions improve immune response in ACLF
via 2 mechanisms. (A) HAS increases circulating albumin concentration and function improving binding of immunosuppressive
PGE2, reducing free/bioactive PGE2 and restoring monocyte/macrophage function. (B) Patients with ACLF can be divided into
hypoinﬂammatory and hyperinﬂammatory responses deﬁned by LM metabolomics, both with potential adverse outcomes.
HAS rectiﬁes this LM imbalance leading to a normalized, appropriate inﬂammatory response with potential improved outcome.
IV, intravenous
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patients were substantially better.
Plasma LM proﬁling of the 4 major essential fatty acid
bioactive metabolomes demonstrated albumin adminis-
tration caused a shift in peripheral blood LM proﬁles. Post
hoc analysis of prealbumin LMproﬁles identiﬁed 2 distinct
groups, a hyperactivated proﬁle with elevated levels of
inﬂammation-initiating eicosanoids and proresolving me-
diators and a hypoactivated proﬁle with reduced LMs. Al-
bumin administration led to distinct regulation of LM
proﬁles in each group suggesting that it may activate
different protective mechanisms in these groups. Immu-
nophenotyping sepsis studies have shown both hyper-
activated and hypoactivated proﬁles can lead to a negative
outcome23,24; indeed recent evidence has shown that a
hyperactivated plasma lipid signature predicts death in
sepsis.25 Albumin may therefore have further beneﬁcial
immune effects. The potential role of these LMs in
inﬂammation and infection and possible utility of LMimmunophenotyping has never previously been described
in liver disease. Although the hyperactivated group had
elevated concentrations of endotoxin and cytokine pre-
treatment, these levels were unaffected by HAS infusion.
These data therefore offer a completely novel opportunity
to study the effect of albumin on the immune system.
Figure 5 provides a schematic version of our hypothesis.
In summary using samples from our multicenter
feasibility study we present novel evidence that targeted
albumin infusions seem to exert a beneﬁcial immune
effect in patients with AD/ACLF via its ability to bind
PGE2, but do not reduce overall total circulating levels.
We identify for the ﬁrst time proresolving LMs in
advanced liver disease and propose that LM metabolic
analysis could immunophenotype these patients. Finally,
a second novel potential immune restorative role in
which albumin infusions rectify both hyperinﬂammatory
and hypoinﬂammatory LM proﬁles was demonstrated.
We believe our study provides the ﬁrst evidence for an
May 2018 Albumin Counteracts Immune-Suppression 747immune-based mechanism of 20% HAS in AD/ACLF.
However, a control arm was not included in the study
design. Sample collection from ATTIRE stage 2, our
randomized controlled trial to assess whether our 20%
HAS infusion regimen leads to a reduction in infection,
renal dysfunction, and death in patients with AD/ACLF
compared with standard care, will provide further
opportunity to investigate the role of these LMs in AD/
ACLF.
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Plasma-Induced Monocyte-Derived
Macrophage Dysfunction
Brieﬂy, cultured human MDMs were stimulated with
1 ng/mL of LPS (Salmonella abortus equi S-form
[TLRgrade], Enzo Life Sciences) for 4 hours in the pres-
ence of 25% patient plasma pretreatment and post-
treatment, and TNF production was measured
(enzyme-linked immunosorbent assay, R&D Systems) as
shown previously. Improvement in macrophage function
was predeﬁned as a signiﬁcant increase in LPS-induced
TNF production. Experiments were performed in the
presence of plasma from healthy control subjects as a
comparator. Pairs of patient plasma samples were iden-
tiﬁed that contained a pretreatment sample (serum
albumin <30 g/L) and a subsequent post-treatment
sample when serum albumin was ﬁrst measured
at >30 g/L.Plasma Protein Binding Capacity
To determine the amount of PGE2 bound, equilibrium
dialysis using a Thermo Scientiﬁc Single-Use Rapid
Equilibrium Dialysis Plate was used, which enabled
quantiﬁcation of bound versus free PGE2 via postdialysis
sample scintillation counting. Patient plasma was incu-
bated with H3-PGE2 mixed with unlabeled PGE2 (molar
ratio, 2727:1; ﬁnal concentration, 2.73 mM). This was
then dialyzed against phosphate-buffered saline in the
Rapid Equilibrium Dialysis Plate for 4 hours at 37C.
Counts in sample chamber and buffer chamber were
measured enabling percentage or total concentration of
PGE2 bound to be calculated (% bound ¼ 100 – [cpm
buffer chamber/cpm plasma chamber]  100).Lipopolysaccharide Detection
HEK293 cells are transfected to stably express TLR4
and a nuclear factor-kB-inducible secreted embryonic
alkaline phosphatase reporter gene. QUANTI-Blue
detection medium changes color in the presence of
secreted embryonic alkaline phosphatase in the spec-
trum of 620–655 nm. Because the absorbance is in direct
proportion to the amount of endotoxin present, the
concentration of endotoxin can be calculated from a
standard curve obtained using serial dilutions of the
HEK-Blue Endotoxin Standard (a preparation of Escher-
ichia coli 055:B5 LPS standardized against Food and
Drug Administration–approved control standard endo-
toxin). Samples were diluted in endotoxin-free water
(Sigma, UK) and then incubated with the HEK293 cells
for 24 hours. The supernatant from these cells was thenincubated with the detection reagent for 4 hours before
being read for absorbance at 640 nm on a FLUOStar
Omega Plate reader (BMG Labtech, Ortenberg, Germany).
Cytokine Measurement
Beads with the appropriate cytokines (IL1b, IL6, IL8,
IL10, TNF-a) were mixed with standards as provided to
produce a standard curve. Samples were diluted in
sample diluent. Assay was then performed as per the
instructions. Beads were read on a BD FACSVerse ﬂow
cytometer (3 lasers: 405 nm, 488 nm, and 640 nm;
10-parameter analysis; BD Biosciences). Data were
acquired using BD FACSuite (BD Biosciences). Data were
analyzed using FCAP Array software v3.0 (Soft Flow Inc,
Hungary).
Lipid Mediator Metabolomic Data
Plasma was placed in 4 volumes of ice cold methanol
containing deuterium-labelled internal standards:
d4-PGE2, d5-LXA4, d5-RvD2, d4-LTB4, d5-LTC4, d5-LTD4,
d5-LTE4, and d8-5S-HETE (500 pg each; Cayman Chem-
icals). These were then kept at 20C for 45 minutes to
allow for protein precipitation and lipid mediators were
extracted using C-18 based Solid Phase Extraction as in
Colas et al12 (PubMed identiﬁer: 24696140). Methyl
formate fractions were brought to dryness using a
TurboVap LP (Biotage) and products suspended in
water-methanol (50:50 vol/vol) for liquid chromatogra-
phy–tandem mass spectrometry based proﬁling. Here a
Shimadzu LC-20AD HPLC and a Shimadzu SIL-20AC
autoinjector (Shimadzu, Kyoto, Japan), paired with a
QTrap 5500 (ABSciex, Warrington, UK) were used and
operated as described in Colas et al12 (PubMed identiﬁer:
24696140). To monitor each lipid mediator and
deuterium-labelled internal standard, a multiple reaction
monitoring method was developed using parent ions and
characteristic diagnostic ion fragments as in Colas et al12
(PubMed identiﬁer: 24696140). This was coupled to an
information-dependent acquisition and an enhanced
product ion scan. Identiﬁcation criteria included match-
ing retention time to synthetic standards and at least 6
diagnostic ions in the tandem mass spectrometry spec-
trum for each molecule. Calibration curves were
obtained for each molecule using authentic and synthetic
compound mixtures and deuterium-labelled lipid medi-
ator at 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50, 100, and 200
pg. Standards for liquid chromatography–tandem mass
spectrometry proﬁling were produced biogenically,
purchased from Cayman Chemicals, or provided by Dr
Charles N. Serhan (supported by National Institutes of
Health funded P01GM095467 to CNS). Linear calibration
curves were obtained for each lipid mediator, which gave
r2 values of 0.98–0.99.
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Supplementary Figure 1. Targeted 20% HAS infusions reverse immune dysfunction in AD/ACLF by improving AD/ACLF
plasma PGE2 binding. (A) TNF production from MonoMac-6 cell line (MM6) stimulated with LPS in the presence of patient
plasma pretreatment and post-treatment with 20% HAS (n ¼ 45 patients as above). Mean increase in MM6 TNF-a production
was 0.211 ng/mL (10.2%; CI, 0.0517–0.369 ng/mL; P ¼ .014). (B) TNF production from healthy volunteer MDMs stimulated
with LPS in the presence of patient plasma pretreatment and post-treatment with 20% HAS (n ¼ 7 patients; patients that did
not increment serum albumin to 30 g/L and had a pretreatment and post-treatment sample available for analysis). Sample
numbers too small for statistical analysis. (C) Percentage of PGE2/
3H-PGE2 bound to patient plasma protein using equilibrium
dialysis, comparing patient plasma pretreatment and post-treatment with 20% HAS. Data shown with undiluted samples and
when all samples had been diluted to the same albumin concentration (18 g/L). (D) TNF production from healthy volunteer
MDMs stimulated with LPS in presence of healthy plasma (n ¼ 4) and presence/absence of AH6890 (50 mM) and MF498 (10
mM) and 1 ng/mL PGE2. (E) TNF production from healthy volunteer MDMs stimulated with LPS in the presence of patient
plasma post-treatment with 20% HAS, samples Day 2 and 4 post-treatment. HV, healthy volunteer; Tx, treatment.
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Supplementary Table 1. Baseline Demographics and
Clinical Characteristics of the
Analysis Population (n ¼ 79)
Characteristic Mean (SD)
Age, y 53.41 (11.63)
Serum albumin, g/L 23.95 (3.51)
Days since admission 1.81 (0.88)
MELD 20.90 (6.62)
Creatinine 91.2 (78.2)
n (%)
Male 52 (66)
Admitted to ICU 2 (3)
Prescribed antibiotics 41 (52)
Diagnosis of infection 27 (34)
Etiology of cirrhosisa n (%)
Alcohol 76 (96)
Hepatitis B 1 (1)
Hepatitis C 11 (14)
NAFLD 4 (5)
Other etiologies 2 (3)
Organ failure according to proposed deﬁnitions n (%)
Renal 8 (10)
Respiratory 9 (11)
Circulatory 13 (16)
Brain 3 (4)
ACLF gradeb n (%)
Grade 0 58 (73)
Grade 1 11 (14)
Grade 2 6 (8)
Grade 3 4 (5)
ACLF, acute-on-chronic liver failure; ICU, intensive care unit; MELD, Model for
End-Stage Liver Disease; NAFLD, nonalcoholic fatty liver disease; SD,
standard deviation.
aSome patients have more than 1 liver cirrhosis etiology.
bAccording to European foundation for the study of chronic liver failure criteria.
Supplementary Table 2. Differences in Blood Test Values Pre-HAS Infusion and After Albumin Restored 30 g/L in Samples
Used for Immune Function Analysis
Mean (SD) Pre–20% HAS infusion,
serum albumin <30 g/L
Mean (SD) serum albumin
restored 30 g/L
P value
(paired Student t test)
White cell count 9.3 (6.4) 8.6 (7.5) .23
CRP 44 (52) 30 (31) .39
Bilirubin 166 (154) 145 (116) .02
CRP, C-reactive protein; HAS, human albumin solution; SD, standard deviation.
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Supplementary Table 3. Plasma LM Proﬁles in Prealbumin Administration LM Levels Were Assessed Using LM
Metabololipidomics
DHA bioactive
metabolome Q1 Q3
Group 1 Group 2
2-2529
AOB
3-2445
AOB
8-1822
AOB
9-2417
AOB
10-2200
AOB
5-1026
AOB
4-1486
AOB
1-2320
AOB
6-2419
AOB
7-1702
AOB
RvD1 375 141 — — 2.2 0.8 2.7 3.3 1.7 19.1 1.0 1.8
RvD2 375 141 2.9 1.7 2.1 0.9 3.8 — — — 4.9 11.2
RvD3 375 147 — — 2.8 5.1 0.7 3.1 3.4 1.1 0.0 0.6
RvD4 375 101 — — 0.2 0.7 0.8 1.0 0.5 1.5 1.3 0.2
RvD5 359 199 7.2 6.8 — 1.3 — 12.4 3.3 13.8 4.6 8.6
RvD6 359 101 — — 0.8 — 0.6 23.1 115.0 — 5.0 —
17R-RvD1 375 141 139.6 0.2 — — — — — — — —
17R-RvD3 375 147 — — 15.1 0.3 — — — — — 2.6
PD1 359 153 0.3 3.8 — — — — 10.7 7.4 3.3 1.0
17R-PD1 359 153 — 1.1 7.8 3.9 3.6 — — 1.6 3.5 —
10S,17S-diHDHA 359 153 — 1.1 — — 11.1 — — — — —
22-OH-PD1 375 153 1.7 — — — — 0.9 — — — —
MaR1 359 221 — — — — — 1.1 — — — —
7S,14S-diHDHA 359 221 — — — 11.5 — — — 6.6 — —
4S,14S-diHDHA 359 101 10.3 — 4.9 4.9 — 1.8 — — — 4.7
n-3 DPA bioactive
metabolome
RvT1 377 239 3.0 1.4 1.2 2.8 0.3 3.5 3.5 4.4 2.1 0.3
RvT2 377 197 0.6 — — — — 1.4 — — 0.3 0.3
RvT3 377 197 2.3 0.7 3.3 — 1.5 — 2.0 20.6 0.3 1.0
RvT4 377 211 9.5 3.0 33.3 — 8.4 — 7.9 77.7 1.5 5.1
RvD1n-3 DPA 377 143 47.4 2.3 12.7 5.0 — 2.9 3.7 35.5 — 6.8
RvD2n-3 DPA 377 215 2.2 2.2 — 0.8 — 1.7 2.2 — — 2.3
RvD5n-3 DPA 361 199 — — 26.0 — — 9.5 — 266.9 3.4 —
PD1n-3 DPA 361 183 10.9 34.2 413.2 13.8 — 259.8 265.9 — 192.7 327.9
10S,17S-diHDPA 361 183 — — — — — — — — — —
MaR1n-3 DPA 361 223 154.1 7.4 — 12.1 — — — 30.4 13.6 —
7S, 14S-diHDPA 361 223 — 8.3 — 6.2 — 15.0 41.4 18.4 5.5 28.7
EPA bioactive
metabolome
RvE1 349 195 1.6 — 1.1 — 20.7 1.5 0.8 7.6 — 0.6
RvE2 333 199 6.6 — 11.1 — 118.1 9.1 3.2 29.1 — 3.0
RvE3 333 201 2.5 26.2 37.9 2.4 5.0 3.1 18.8 7.1 23.7 13.8
AA bioactive
metabolome
LXA4 351 217 0.8 — — — 1.0 — 1.2 — 1.7 8.0
LXB4 351 221 16.0 — 147.4 — — — 64.0 169.6 44.0 167.8
5S,15S-diHETE 335 235 10.8 — 148.3 35.0 29.4 486.1 118.4 110.1 29.6 83.1
AT-LXA4 351 217 — — 17.7 — — 12.0 6.1 3.5 — 3.5
AT-LXB4 351 221 — — — — 6.6 — — — — 21.9
LTB4 335 195 40.6 33.4 9.1 15.9 93.3 27.5 40.2 7.0 281.3 596.6
5S,12S-diHETE 335 195 4.5 0.4 2.4 11.1 3.3 5.3 2.4 1.3 9.7 13.0
20-OH-LTB4 351 195 3.6 43.0 3.8 15.3 50.4 11.6 87.1 4.0 486.7 1106.0
LTC4 626 189 12.2 35.8 38.7 139.5 28.9 88.6 — 11.7 — 23.0
LTD4 497 189 — 12.4 17.7 17.2 7.8 — — — — —
LTE4 440 189 0.8 59.3 144.1 62.9 61.1 240.2 34.9 10.7 97.9 0.1
PGD2 351 189 8.1 13.1 4.1 30.1 14.9 55.5 36.9 6.0 34.0 34.7
PGE2 351 189 14.0 23.4 32.4 11.4 24.8 111.9 105.2 7.5 112.5 81.5
PGF2a 353 193 25.5 26.9 60.4 55.1 63.2 167.5 180.4 62.8 48.2 71.2
TxB2 369 169 1142.4 623.8 2566.2 780.2 1781.9 1939.9 6946.8 408.4 15370.6 9075.9
NOTE. Results are expressed as pg/mL. Em dash ¼ below limit; limitz 0.1 pg. With Q1, M-H (parent ion); and Q3, diagnostic ion in the tandem mass spectrometry
(daughter ion).
AA, arachidonic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid.
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Supplementary Table 4. Plasma LM Proﬁles Post Albumin Administration
DHA bioactive
metabolome Q1 Q3
Group 1 Group 2
2-2529
AOB
3-2445
AOB
8-1822
AOB
9-2417
AOB
10-2200
AOB
5-1026
AOB
4-1486
AOB
1-2320
AOB
6-2419
AOB
7-1702
AOB
RvD1 375 141 0.3 — 0.4 2.1 1.1 — 2.5 9.4 0.4 3.4
RvD2 375 141 — 0.6 2.5 — 3.6 — 4.6 — 2.7 7.4
RvD3 375 147 — 0.7 — 6.7 — 3.4 3.1 0.8 0.4 —
RvD4 375 101 0.1 1.4 2.2 1.9 3.6 0.4 0.6 2.4 0.9 0.9
RvD5 359 199 3.6 3.6 5.6 14.1 18.2 7.4 7.8 1.6 7.5 17.5
RvD6 359 101 4.5 2.8 3.3 0.6 6.2 24.7 31.7 2.7 10.2 1.8
17R-RvD1 375 141 — 1.7 — 1.0 — — — — 1.2 1.2
17R-RvD3 375 147 0.2 — — 0.5 — 0.3 — 1.0 — 2.8
PD1 359 153 1.3 2.1 0.3 1.1 2.1 — — 2.8 4.9 8.8
17R-PD1 359 153 5.1 3.9 — 1.5 3.4 — — — — 1.5
10S,17S-diHDHA 359 153 — — — — 0.9 — — — 0.6 —
22-OH-PD1 375 153 — — — — 0.2 — 1.2 2.7 — 1.2
MaR1 359 221 — — — — 1.7 2.9 — — — —
7S,14S-diHDHA 359 221 3.1 — 1.9 20.0 3.2 — — 8.6 3.2 —
4S,14S-diHDHA 359 101 — — 1.6 6.6 — — — 19.5 — 3.8
n-3 DPA bioactive
metabolome
RvT1 377 239 0.5 0.5 0.6 0.5 0.5 7.4 1.7 0.7 0.8 8.8
RvT2 377 197 0.2 1.0 1.1 — 1.1 1.4 0.8 2.5 1.5 —
RvT3 377 197 0.6 0.3 0.6 — 0.8 — 0.6 3.8 0.3 2.7
RvT4 377 211 2.8 1.5 2.0 — 1.9 — 4.2 15.7 1.2 10.7
RvD1n-3 DPA 377 143 16.7 20.3 7.5 15.3 9.1 4.8 4.5 18.9 9.2 3.2
RvD2n-3 DPA 377 215 — 0.2 — 1.1 2.7 1.0 1.1 3.2 — 1.8
RvD5n-3 DPA 361 199 3.7 9.3 — 3.3 0.8 8.5 — 3.2 2.5 4.6
PD1n-3 DPA 361 183 24.4 47.3 299.5 108.5 41.5 574.0 422.6 — — 367.1
10S,17S-diHDPA 361 183 — — — — — — — — — —
MaR1n-3 DPA 361 223 — 4.7 10.3 78.1 2.7 — 13.0 — — 109.7
7S, 14S-diHDPA 361 223 — 6.5 9.7 81.7 — — 84.7 — 1.8 39.2
EPA bioactive
metabolome
RvE1 349 195 0.9 — 0.5 0.5 0.4 25.4 5.4 1.0 8.7 0.6
RvE2 333 199 3.9 — 1.9 1.2 1.0 207.1 39.1 4.3 32.3 2.5
RvE3 333 201 0.8 4.0 13.3 — — — 3.5 — 2.9 181.5
AA bioactive
metabolome
LXA4 351 217 0.7 — — 0.4 — 1.5 0.4 — 1.5 0.7
LXB4 351 221 13.5 6.8 6.8 11.0 189.1 0.0 11.0 189.1 0.0 13.5
5S,15S-diHETE 335 235 58.8 182.7 47.9 71.2 21.4 282.4 126.7 58.6 11.0 45.2
AT-LXA4 351 217 — — — 3.5 — 17.6 3.5 — 17.6 —
AT-LXB4 351 221 — — — — — 129.3 — — 129.3 —
LTB4 335 195 8.4 12.4 4.6 11.2 52.4 20.5 15.2 6.7 84.2 85.5
5S,12S-diHETE 335 195 13.2 4.3 2.0 11.2 52.4 5.7 10.3 8.1 56.8 4.2
20-OH-LTB4 351 195 15.6 4.2 — — — 19.5 5.2 26.5 129.3 —
LTC4 626 189 310.6 143.6 104.0 108.4 29.1 67.5 187.3 71.6 86.1 158.3
LTD4 497 189 — — 181.7 — — — — — 11.8 —
LTE4 440 189 16.3 15.4 111.6 115.8 0.4 560.8 29.6 12.3 54.9 —
PGD2 351 189 21.2 34.8 26.8 13.9 47.3 36.9 13.5 14.5 27.4 32.8
PGE2 351 189 58.9 55.4 71.8 8.2 69.4 69.5 25.1 3.8 72.0 65.1
PGF2a 353 193 28.0 92.6 114.2 41.4 107.8 65.6 58.1 37.6 31.6 84.8
TxB2 369 169 3167.6 938.9 9291.8 943.0 4320.1 1790.9 3309.4 782.5 8298.5 5740.6
NOTE. LM levels were assessed using LM-metabololipidomics. Results are expressed as pg/mL. Em dash ¼ below limit; limitz 0.1 pg. With Q1, M-H (parent ion);
and Q3, diagnostic ion in the tandem mass spectrometry (daughter ion).
AA, arachidonic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; LM, lipid mediator; PG, prostaglandin.
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Supplementary Table 5. Theoretical Calculations Comparing the Effects of Low and High Binding Afﬁnity Albumin on Free
Circulating Levels of PGE2 Based on Concentrations of PGE2 and Serum Albumin Found in Healthy
Patients and Patients With ACLF
Albumin at 40 g/L (w600 mM) (Healthy)
PGE2,
pg/mL
PGE2,
pM
High
binding
afﬁnity,
Kd mM
Free
PGE2,
pg/mL
Low
binding
afﬁnity,
Kd mM
Free
PGE2,
pg/mL
2 5.7 0.00007 1.4
10 28.4 0.02 0.0003 200 2.5
20 56.7 0.0007 5
Albumin at 20 g/L (w300 mM) (ACLF)
PGE2, pg/mL PGE2, pM Kd mM Free PGE2, pg/mL Kd mM Free PGE2, pg/mL
2 5.7 0.0001 0.80
10 28.4 0.02 0.0007 200 4.0
20 56.7 0.0013 7.99
ACLF, acute-on-chronic liver failure; PGE2, prostaglandin E2.
Supplementary Table 6. Plasma Cytokine and LPS Concentrations at Baseline and Following 20%-HAS Treatment Once
Serum Albumin >30 g/L
Mean plasma level
pretreatment, pg/mL (n ¼ 45)
Mean plasma level
post-treatment, pg/mL ( n ¼ 45)
Mean change
post-treatment, pg/mL CI, pg/mL
TNF-a 1.32 1.30 -0.01 -0.42 to 0.40
IL6 100.88 85.10 -17.46 -49.05 to 14.13
IL8 708.76 458.61 -252.80 -555.70 to 50.21
IL10 2.78 3.24 þ0.45 -0.64 to 1.53
IL1b 1.28 1.14 -0.16 -0.99 to 0.68
LPS 17.71 15.69 -2.022 -4.792 to 0.7477
CI, conﬁdence interval; HAS, human albumin solution; IL, interleukin; LPS, lipopolysaccharide; TNF, tumor necrosis factor.
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